Metoprolol Shows No Clear Benefit for COPD Patients Without Cardiovascular Disease
A randomized trial called BRONCHIOLE found that adding metoprolol to standard care did not significantly reduce the combined risk of exacerbations, cardiovascular events, or death in COPD patients without established heart disease. Although individual outcome components trended favorably for metoprolol, none reached statistical significance, and the drug was associated with more adverse events like fatigue and low blood pressure. The findings, presented at the ERS Congress and published in NEJM Evidence, align with earlier trials that failed to show benefit in this population.
The open-label trial enrolled 1,695 participants across 30 Swedish sites, with a mean age of 70 and 62% women. Notably, only about half of those assigned metoprolol reached the target daily dose of 100 mg, which may have influenced the outcomes.
Editorialists characterized this as the fourth negative trial for beta-blockers in COPD, yet stressed the drug's reassuring safety profile. They advised that clinicians should not withhold beta-blockers from patients who have clear cardiac indications, while future research should focus on identifying potential responders through comprehensive phenotyping.
This negative result could influence prescribing habits for COPD patients without heart disease, potentially sparing them from side effects like fatigue and hypotension. However, it may also reassure physicians that beta-blockers are safe for those who need them for cardiac reasons. The findings could shift research priorities toward identifying specific COPD phenotypes that might respond, rather than broadly applying the drug. Patients with coexisting heart conditions remain unaffected, as guidelines still support use in that population.